Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 5/20 | 0.31 |
| ▸ | CA1 | P00915 | 5/20 | 0.31 |
| ▸ | CA2 | P00918 | 5/20 | 0.31 |
| ▸ | CA9 | Q16790 | 5/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.31 |
| ▸ | CA7 | P43166 | 4/20 | 0.31 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22267759 | 0.80 | — | — | |
| SCHEMBL18924870 | 0.80 | — | — | |
| SCHEMBL25657139 | 0.80 | TSHR (0.40) | TSHRLMNAHTTNPSR1HCAR2 | |
| SCHEMBL6244866 | 0.78 | — | — | |
| SCHEMBL8386796 | 0.77 | TSHR (0.37) | TSHRLMNAHTTNPSR1HCAR2 | |
| SCHEMBL8386794 | 0.77 | TSHR (0.37) | TSHRLMNAHTTNPSR1HCAR2 | |
| SCHEMBL25692130 | 0.77 | ALOX5 (0.45) | TSHRLMNAHTTNPSR1HCAR2 | |
| SCHEMBL3636117 | 0.76 | — | — | |
| SCHEMBL12988855 | 0.76 | TSHR (0.46) | TSHRLMNAHTTNPSR1HCAR2 | |
| SCHEMBL8593195 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104530417-B | A kind of multiple functionalized H types polyethyleneglycol derivative and preparation method thereof | 厦门赛诺邦格生物科技股份有限公司 | 2017-09-08 | — | — | CN | claimed |
| CN-104530415-B | A kind of different functionalization Y types polyethyleneglycol derivative, preparation method and its bio-related substance | 厦门赛诺邦格生物科技股份有限公司 | 2017-09-01 | — | — | CN | claimed |
| CN-114736219-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-114751920-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117865987-A | Antitumor compounds | 法马马有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| CN-1882524-A | 4- ((phenoxyalkyl) thio) -phenoxyacetic acids and analogs | JANSSEN PHARMACEUTICA NV (BE) | 2006-12-20 | — | — | CN | disclosed |
| CN-1127502-C | Paroxetine methanesulfonate | SMITHKLINE BEECHAM PLC (GB) | 2003-11-12 | — | — | CN | disclosed |
| CN-1077439-C | Labeled chemotactic peptides for imaging of sites of infection or inflammation lesions | GEN HOSPITAL CORP (US) | 2002-01-09 | — | — | CN | disclosed |
| CN-1315949-A | Salts of paroxetine | SMITHKLINE BEECHAM PLC (GB) | 2001-10-03 | — | — | CN | disclosed |
| CN-1141002-A | Labeled chemotactic peptides for imaging of sites of infection or inflammation lesions | GEN HOSPITAL CORP (US) | 1997-01-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | SREBF1, SREBF2, XBP1 | TSHR 1549/4885LMNA 499/4885HTT 4287/4885 |
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | TSHR 1491/4885LMNA 918/4885HTT 1965/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | TSHR 1768/4885LMNA 4438/4885HTT 854/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | TSHR 3663/4885LMNA 3835/4885HTT 3216/4885 |
| US-20080015179-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | TSHR 131/4885LMNA 4093/4885HTT 3195/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | TSHR 3332/4885LMNA 3803/4885HTT 2559/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | TSHR 965/4885LMNA 3579/4885HTT 4184/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | TSHR 1390/4885LMNA 1053/4885HTT 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.